ACS secondary-prevention bundle
The 2025 Australian numbers, and the beta-blocker / colchicine / ARNI shifts.
What actually applies (2025 AU)
- LDL-C target < 1.4 mmol/L and ≥ 50% reduction from baseline: highest tolerated statin, then add ezetimibe, then a PCSK9 inhibitor (evolocumab or inclisiran) if still suboptimal.
- Beta-blockers are no longer routine for everyone. LV impairment → indicated; preserved LV function, revascularised, on optimal therapy → a weak recommendation to consider withholding.
- ACE inhibitor/ARB for HF symptoms, LVEF ≤ 40%, diabetes, hypertension or CKD; add an MRA if LVEF ≤ 40% with HF.
- ARNI is NOT recommended post-ACS (new 2025 change).
- Colchicine 0.5 mg daily long-term is a new weak recommendation; refer all to cardiac rehab, plus DAPT, smoking cessation and vaccination.
The discriminator
- LV impairment → beta-blocker; preserved + revascularised + on OMT → consider withholding.
- Statin + ezetimibe insufficient → add a PCSK9 inhibitor (don’t just up-titrate the statin).
- LVEF ≤ 40% + HF → add an MRA; ARNI not recommended.